Genera Research and the EIC Accelerator: Turning Blood Into Bone

Genera istraživanja, known as Genera Research, a company founded in Croatia in October 2001 and directed by Slobodan Vukičević and Dora Adanić, develops OSTEOGROW, a bone regeneration drug made of recombinant human bone morphogenetic protein 6 (rhBMP6) delivered in a clot of the patient's own blood instead of the bovine collagen carrier used by earlier BMP products. Its EIC Accelerator project, OSTEOforUNION, "Drug solution for bone fracture nonunions", receives an EU contribution of €2,499,999 and runs from January 2025 to December 2026, according to CORDIS. It targets OSTEOGROW-C, a version with tricalcium phosphate ceramics for fractures that fail to heal, where no biological drug is approved and surgeons harvest bone from the patient's hip.

The report says the project optimised and scaled rhBMP6 production to pharmaceutical GMP standards, refined the OSTEOGROW-C kit, and selected clinical sites in the EU, UK and US that have supplied lists of eligible patients, according to CORDIS. The pivotal Phase II/III trial, called OCEAN, "is under regulatory exploration", and its protocol "is under discussion with EMA, MHRA and FDA". The overall objective is to complete late-stage clinical development so that OSTEOGROW-C becomes the first approved biological treatment for nonunions. No OSTEOGROW trial is listed on ClinicalTrials.gov or the EU Clinical Trials Information System.

Where Genera Research Stands Now

Genera's total income, which includes grants, rose from €706,032 in 2023 to €2,248,952 in 2025, with a profit of €82,506 and 11 employees, up from 3, according to FINA filings on Companywall. It reports no receivables from customers. The register lists Slobodan Vukičević, Reinhard Windhager and Dora Adanić among its owners; no outside equity round or EIC Fund investment has been announced.

The Technology: A Clot as the Carrier

Earlier BMP drugs used bovine collagen as a carrier, which Genera calls inflammatory. OSTEOGROW binds rhBMP6 to a blood clot prepared in the operating room, and the -C version adds ceramic granules for mechanical strength. OSTEOGROW has been tested in 20 patients after high tibial osteotomy and 32 with wrist fractures, and OSTEOGROW-A in a 143-patient Phase II spinal fusion trial, according to Genera Research. Much of that work ran through EU research projects led by the University of Zagreb, including OSTEOproSPINE, a €6.0 million Horizon 2020 project from 2018 to 2023, according to CORDIS.

What the EIC Award Promised, and What the Record Shows

The project runs to December 2026, so it is too early to judge it. Manufacturing scale-up and site selection are reported. The central goal, late-stage clinical development, depends on a pivotal trial that has not been approved or registered, which means no patient in it can finish follow-up within the project.

1. GMP rhBMP6 productionScalingProject report.
2. OSTEOGROW-C kitRefinedProject report.
3. Pivotal Phase II/III trialNot startedNot registered.
4. Regulatory alignmentIn talksEMA, MHRA, FDA.

The Money

Genera's income tripled in two years while its filings show no receivables from customers, and its clinical programme has run largely through EU research grants. The EIC award was blended finance, but no EIC Fund investment or private round has been announced to pay for a pivotal trial across the EU, UK and US.

What Cannot Be Checked

Why Europe Should Care

The project description counts 180,000 diagnosed long bone nonunions a year in Europe. A drug that replaces bone harvesting would spare patients a second surgical site. The drug is not yet approved, and much of its clinical work ran through EU-funded research projects.

The Verdict

Genera Research and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.